News Agency
The Times

Altos Biologics, a Subsidiary of Alteogen, Completed Patient Enrollment in Global Phase 3 Clinical Trial of Eylea® Biosimilar in Neovascular Age-related Macular Degeneration

  • Written by PR Newswire
  • Altos Biologics, a subsidiary of Alteogen, is actively engaged in Eylea® Biosimilar (ALT-L9) clinical development and licensing-out discussions.
  • Early 2024 projected for Phase 3 completion and product launch in Europe expected after obtaining approval in the first half of 2025.

DAEJEON, South Korea, Feb. 22, 2023 /PRNewswire/ -- Alteogen...

Read more: Altos Biologics, a Subsidiary of Alteogen, Completed Patient Enrollment in Global Phase 3 Clinical...

How Does Temporary Fencing Help Simplify Project Planning?

Why Does Temporary Fencing Matter During Project Planning?  A controlled boundary is essential when construction, infrastructure maintenance, demolition,  landscaping, and other projects are underway. That is when temporary fencing becomes an important  option to consider. The fencing layout affects more than site... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion